Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer.~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients with de novo refractory disease (progression of disease as best response at 1st line therapy with FOLFOX/Avastin)~* Adequate liver (Bilirubin ≤ 1.5 UNL, SGOT/SGPT ≤ 4 UNL, ALP ≤ 2.5 UNL),renal (Creatinine ≤ 1.5 UNL) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, congestive heart failure, uncontrolled cardiac arrhythmias).~* History of myocardial infarction or stroke within 6 months.~* Clinically significant peripheral vascular disease.~* History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0.~* Presence of central nervous system or brain mets.~* Evidence of bleeding diathesis or coagulopathy.~* Patients with known hypersensitive reaction to cetuximab~* Blood pressure \> 150/100 mmHg.~* Pregnant or lactating woman.~* Life expectancy \< 3 months.~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow.~* Metastatic infiltration of the liver \>50%.~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy.~* Active infection requiring antibiotics on Day 1.~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer.~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Irinotecan+Avastin+Erbitux

Based on this trial design, predict the completion outcome and termination type (if applicable).